The Multidisciplinary Association for Psychedelic Studies (MAPS) is currently conducting Phase III clinical trials to investigate the efficacy of MDMA-assisted psychotherapy for the treatment of severe post-traumatic stress disorder (PTSD). Dr. Genesee Herzberg, the executive director of Sage Institute, is also a therapist and co-investigator for one of the San Francisco sites conducting this research. MAPS has applied to the FDA's Expanded Access program, which would allow individuals who are not able to participate in the research access to this form of treatment for PTSD. If MAPS' application for Expanded Access is granted by the FDA, Sage Institute will apply to become one of the sites approved to offer MDMA-assisted psychotherapy legally to those suffering from post-traumatic stress disorder. If you are interested in learning about new treatment options as they become available, you can join our mailing list at www.sageinst.org/contribute.